A phase I study of a next-generation CAR T cell therapy showed a 52 percent complete remission rate for patients with relapsed/refractory lymphoma.
Enhanced CAR T cell therapy offers new strategy for lymphoma
- Post author:Annie Holland
- Post published:May 8, 2025
- Post category:News Feed
- Post comments:0 Comments